Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).

Trial Details

NCT ID
NCT07548177
Phase
PHASE2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Benmelstobart injection combined with Anlotinib hydrochloride capsule
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Guangdong, Guangdong, China
  • Harbin, Heilongjiang, China|45.75,126.65
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Only when all the following criteria are met will the subjects be eligible for inclusion in this study:
  • The subjects voluntarily join this study, sign the informed consent form, and have good compliance;
  • ≥14 years old (calculated from the date of signing the informed consent form);
  • Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →